Characteristics of all 190 patients with advanced nonsmall cell lung cancer who received treatment with pemetrexed
| Primary cohort | Independent cohort | ||
| No maintenance pemetrexed | Maintenance pemetrexed | Maintenance pemetrexed | |
| Patients | 105 | 44 | 41 |
| Age years | 63.7±9.4 | 62.9±7.5 | 62.8±6.7 |
| Male | 52 (49.5) | 22 (50.0) | 14 (34.1) |
| Ethnicity | |||
| Caucasian | 100 (95.2) | 42 (95.5) | 38 (92.7) |
| Black | 1 (1.0) | 0 | 0 |
| Asian | 2 (1.9) | 0 | 0 |
| Other | 2 (1.9) | 2 (4.5) | 3 (7.3) |
| BMI kg·m−2 | 24.3±3.9 | 25.3±3.7 | 24.8±5.3 |
| Pack-years | 38.3±36.4 | 34.7±23.3 | 34.0±21.0 |
| Type of tumour | |||
| Adenocarcinoma | 102 (97.1) | 44 (100) | 41 (100) |
| Large cell carcinoma | 3 (2.9) | 0 | 0 |
| Cancer stage | |||
| Locally advanced (IIIA) | 0 | 0 | 1 (2.4)# |
| Locally advanced (IIIB) | 20 (19.0) | 0 | 1 (2.4) |
| Metastatic (IV) | 85 (81.0) | 44 (100) | 39 (95.1) |
| Line of induction treatment | |||
| First line | 105 (100) | 44 (100) | 41 (100) |
| Platinum combination | |||
| Cisplatin | 65 (61.9) | 32 (72.7) | 31 (75.6) |
| Carboplatin | 40 (38.1) | 12 (27.3) | 13 (24.4) |
| Laboratory values | |||
| Creatinine mL·min−1 | 61.0 (49.0–72.5) | 57.5 (52.0–70.0) | 64.0 (51.5–79.0) |
| eGFR mL·min−1 per 1.73 m2 | 96.9 (85.4–104.7) | 97.6 (88.6–106.1) | 95.4 (79.4–101.0) |
| eGFR <60 mL·min−1 per 1.73 m2 | 6 (5.7) | 2 (4.5) | 1 (2.4) |
| Albumin g·L−1 | 38.6±5.3 | 41.3±3.8 | Unknown |
| Comorbidity | |||
| Cardiovascular disease | 47 (44.8) | 16 (36.4) | 18 (43.9) |
| Diabetes mellitus | 17 (16.2) | 4 (9.1) | 5 (12.2) |
Data are presented as n, mean±sd, n (%) or median (interquartile range). BMI: body mass index; eGFR: estimated glomerular filtration rate. #: patient received only palliative chemotherapy (lymphangitis carcinomatosa).